Mycoplasma infections pose significant challenges in the poultry industry, necessitating effective therapeutic interventions. Tiamulin, a veterinary antibiotic, has demonstrated efficacy against Mycoplasma species. However, the emergence of resistant Mycoplasma species could dramatically reduce the therapeutic potential, contributing to economic losses. Optimizing the tiamulin’s pharmacokinetic profile via nanocarrier incorporation could enhance its therapeutic potential and reduce the administration frequency, ultimately reducing the resistant strain emergence. Niosomes, a type of self-assembled non-ionic surfactant-based nanocarrier, have emerged as a promising drug delivery system, offering improved drug stability, sustained release, and enhanced bioavailability. In this study, niosomal nanocarriers encapsulating tiamulin were prepared, characterized and assessed in Mycoplasma-inoculated broilers following oral administration. Differential scanning colorimetry (DSC) confirmed the alterations in the crystalline state following components integration into the self-assembled structures formed during the formulation procedure. Transmission electron microscopy (TEM) showed the spherical nanostructure of the formed niosomes. The formulated nanocarriers exhibited a zeta potential and average hydrodynamic diameter of −10.65 ± 1.37 mV and 339.67 ± 30.88 nm, respectively. Assessment of the pharmacokinetic parameters following oral administration to Mycoplasma gallisepticum-infected broilers revealed the ability of the niosomal nanocarriers to increase the tiamulin’s bioavailability and systemic exposure, marked by significantly higher area under the curve (AUC) (p < 0.01) and prolonged elimination half-life (T1/2) (p < 0.05). Enhanced bioavailability and prolonged residence time are crucial factors in maintaining therapeutic concentrations at reduced doses and administration frequencies. This approach provides a viable strategy to decrease the risk of subtherapeutic levels, thereby mitigating the development of antibiotic resistance. The findings presented herein offer a sustainable approach for the efficient use of antibiotics in veterinary medicine.
1 March 2010 in Journal of Veterinary Medical Research
A total of 90 one-day-old male broiler chicks were fed on balanced ration for 15 days and then divided into 3 equal groups. Control group fed ration probiotic free, group 2 and 3 fed ration supplemented with probiotic at concentration levels 0.5 and 1.0g/kg ration respectively for 4 weeks.It was found that probiotic improve body weight gain and feed conversion ratio. Relative organs weights were not altered in groups of birds fed ration mixed with probiotic. Serum values of biochemical parameter (AST, ALT, ALP, total protein, A/G ratio, Ph) were not significantly changed in comparison to control group. Probiotic enhance the immune response of broiler chickens in a dose dependent relation as documented by increasing the serumNDHI antibody geometric mean titres to ND vaccine, phagocyte percentage and phagocytic index of peripheral blood monocyte of broiler chickens. We concluded that probiotic composed of 3 strains of bacteria (Pediococcus acidilactici, Pediococaoccus pentosaceus and Bacillus Amylolique- faciens) in addition to 2 strains of yeast( Pichia farinose and Dekera anomala ) enhance body weight gain, feed conversion, growth performance and Newcastle disease antibody titres in broiler chickens. Moreover, probiotic was safe as proved by serum biochemical profile and relative organ weight of male broiler chickens.